Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) EBIT: 2016-2024

Historic EBIT for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to -$265.5 million.

  • Rhythm Pharmaceuticals' EBIT fell 19.98% to -$52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$186.2 million, marking a year-over-year increase of 29.87%. This contributed to the annual value of -$265.5 million for FY2024, which is 44.02% down from last year.
  • Rhythm Pharmaceuticals' EBIT amounted to -$265.5 million in FY2024, which was down 44.02% from -$184.4 million recorded in FY2023.
  • In the past 5 years, Rhythm Pharmaceuticals' EBIT registered a high of -$170.1 million during FY2021, and its lowest value of -$265.5 million during FY2024.
  • For the 3-year period, Rhythm Pharmaceuticals' EBIT averaged around -$209.7 million, with its median value being -$184.4 million (2023).
  • Data for Rhythm Pharmaceuticals' EBIT shows a maximum YoY crashed of 44.02% (in 2024) over the last 5 years.
  • Yearly analysis of 4 years shows Rhythm Pharmaceuticals' EBIT stood at -$170.1 million in 2021, then fell by 5.35% to -$179.2 million in 2022, then declined by 2.90% to -$184.4 million in 2023, then plummeted by 44.02% to -$265.5 million in 2024.